{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-168096","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.839309+00:00","generated_at":"2026-05-17T23:35:40.617391+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Larimar Therapeutics reports preliminary cash balance of $138.5M as of June 30, 2025","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of $138.5M as of June 30, 2025.","Disclosed in a preliminary prospectus supplement filed under Rule 424(b)(5) on July 29, 2025.","Financial close for Q2 2025 not complete; amount subject to change."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-168096","json":"https://secwatch.observer/filing/0001193125-25-168096.json","markdown":"https://secwatch.observer/filing/0001193125-25-168096.md","text":"https://secwatch.observer/filing/0001193125-25-168096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312525168096/0001193125-25-168096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312525168096/d927864d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:35:40.617391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}